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the Shc adaptor protein, phosphatidyl
inositol-3 kinase (PI3K), and Akt kinases.
Two substrates of Akt implicated in aging
are forkhead transcription factors (FHTF)
and the mammalian target of rapamycin
(mTOR). FHTF are inhibited by Akt, result-
ing in reduced cellular production of anti-
oxidant proteins, whereas mTOR is acti-
vated by Akt resulting in increased protein
synthesis and cell hypertrophy. It will be
important to establish which of the AT1AR
signaling pathways enhances cardiovas-
cular aging and whether AT1AR deficiency
suppresses age-related changes in other
tissues. In particular, the activation status
of p66Shc andmTORshould be evaluated
in tissues of the AT1AR-deficient mice in
light of the increased longevity of mice
lacking p66Shc (PurdomandChen, 2003).
Is the increased longevity of AT1AR-
deficientmice simply the result of reduced
cardiovascular pathology as suggested
by the authors (Benigni et al., 2009)?
Mice rarely die from cardiovascular
disease—instead in laboratory settings
they typically succumb to cancers, infec-
tions, or renal disease (Brayton, 2007).
The observation that AT1AR deficiency
extended both average and maximum
life span suggests that AT1AR signaling
may accelerate the aging process in cells
throughout the whole body rather than
affecting only age-related cardiovascular
disease. Although Ang II is best known
for its effects on cardiovascular and renal
cells, AT1AR are widely expressed in cells
of the nervous system where they may
influence neuroendocrine function, auto-
nomic/stress responses, and possibly
a range of behaviors, some of which may
be preferentially preserved during aging
in AT1AR-deficient mice. Moreover,
AT1AR have been shown to play an im-
portant role in tumor angiogenesis and
growth (Egami et al., 2003), which could
contribute to the extended survival of the
AT1AR-deficient mice. Finally, the findings
of Benigni et al. open the possibility that
ACE inhibitors and AT1AR antagonists
could increase the longevity of healthy
humans who may not present significant
hypertensive symptomology.
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Osteoclasts are the primary cells that resorb bone; they require high energy levels to degrade bone matrix,
releasing minerals to maintain calcium homeostasis. Recent work on osteoclast differentiation and activity
highlights an important role for mitochondrial biogenesis and explores the role of iron transferrin in gener-
ating a positive osteoclastogenic feedback loop.Osteoclastic bone resorption plays a
critical role in normal bone remodeling
and calcium homeostasis. Osteoclasts
(OCLs) resorb bone by releasing hydrolytic
enzymes to degrade bone matrix and
secrete acid into a specialized extracellular
compartment, the ruffledborder, bymeans
of an energy-dependent vacuolar proton
pump. Similar to other cells specializedfor proton secretion, such as the interca-
lated cells of the kidney, OCLs have abun-
dant mitochondria to provide the high
energy levels required by the vacuolar
proton pump to release mineral from bone
(Brown and Breton, 1996). However, how
mitochondrial numbers in OCLs are
increased and the effect of enhancedmito-
chondriogenesis on OCL formation areCell Metabounknown. In their recent paper in Nature
Medicine, Ishii and coworkers now show
that mitochondrial biogenesis plays a crit-
ical role in OCL differentiation (Ishii et al.,
2009) and that iron transferrin is an impor-
tant component of this process. These
authors found that Ppargc1b, which
encodes peroxisomeproliferator-activated
receptor-g coactivator 1b (PGC-1b), islism 9, May 6, 2009 ª2009 Elsevier Inc. 405
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ation and increasesmitochon-
drial gene expression and
enzyme function in OCLs.
Importantly, knockdown of
Ppargc1b in OCL precursors
significantly inhibited both
OCL formation and sup-
pressed mitochondrial gene
expression when bone
marrow macrophages from
Ppargc1b knockout mice
were cultured in the presence
of RANKL and M-CSF.
Further, reactive oxygen
species (ROS), generated by
mitochondrial activity, acti-
vated CREB, a known regu-
lator of OCL formation (Sato
et al., 2006), and increased
Ppargc1b transcription to
further accelerate osteoclas-
togenesis. Surprisingly,
although mice lacking Ppargc1b had
increased bone mass, they had normal
numbers of OCLs, but the OCLs displayed
defective bone resorption. Interestingly,
although the Ppargc1b/ mice had
increased bone mass, they also displayed
an osteoblast differentiation defect that
resulted in decreased bone formation,
osteoblast surface, and osteoid surface.
However, the OCL defect was predomi-
nant in these animals. The osteoblast
defect inPpargc1b/micewascell auton-
omous and did not result from decreased
OCL function. Osteoblast differentiation
in vitro was abnormal, with decreased
expression of RUNX2 and osteocalcin.
The basis for the normal OCL numbers
present in vivo and defect in osteoclasto-
genesis found with in vitro studies of these
mice is not apparent, although the authors
speculated that the defect in OCL dif-
ferentiation in vivo was compensated
by increased RANKL production in the
marrowmicroenvironment. How upregula-
tion of RANKL occurred and if it can result
in normal numbers ofOCLs in the knockout
mice is unclear.
The investigators then examined trans-
ferrin receptor expression during OCL
differentiation, because heme is a con-
stituent of many respiratory complexes
in mitochondria. Transferrin receptor 1
(TfR1) mRNA was increased by mRNA
stabilization during OCL differentiation,
and iron uptake through TfR1 promoted
OCL differentiation. Expression of c-fos
and NFATc1 mRNA was enhanced by
treating pre-OCL in vitro with iron
transferrin and inhibited by an iron chelator,
desferrioxamine (DFO), confirming the
importance of iron transferrin in OCL differ-
entiation. Further, when iron transferrinwas
used to stimulate osteoclastogenesis,
CREB phosphorylation was increased by
the ROS that were generated in the mito-
chondria, resulting in enhanced expression
of PGC-1b and increased mitochondrial
biogenesis, thereby creating a positive
feedback loop. Iron uptake also promoted
mature OCL function by increasing actin
ring formation and bone resorption.
The investigators then treated ovariec-
tomized (OVX) mice with DFO to deter-
mine if iron regulated OCL activity in vivo,
since OVX mice have increased OCL
formation and bone loss. DFO did block
the bone loss and changes in trabecular
thickness in OVX mice compared to
sham-treated controls. However, the
authors did not report if DFO affected
OCL formation, OCL activity, or both or if
DFO affected osteoblast function as well.
The authors propose a model for this
newly identified link among mitochondrial
biogenesis, iron, and OCL differentiation/
activity. In this model, iron uptake
activates CREB, which in turn increases
expression of PGC-1b. PGC-1b then
enhances mitochondrial biogenesis to
induce OCL differentiation and bone
resorption. The ROS gener-
ated by the increased mito-
chondrial activity further
increase PGC-1b levels to
enhance OCL differentiation.
The authors suggest that
iron overload leads to
increased production and
function of OCLs and may
underlie the accelerated
bone loss observed in thalas-
semic patients. However, this
is probably not the case.
Although osteoporosis is
a frequent complication of
thalassemia and other iron-
overload states (Weinberg,
2008), iron overload results
in gonadal hormone defi-
ciency in these patients,
which more likely is the
primary effect of iron on
bone loss in these patients
(Diamond et al., 1989). Further, it is
unlikely that manipulating iron levels with
DFO, for example, will play an important
role in treating osteoporosis, since
although iron deficiency suppresses
bone resorption, it also inhibits bone
formation in rodent models (Katsumata
et al., 2009). Thus, although the current
paper provides important new insights
into the mechanisms responsible for the
increased mitochondrial biogenesis and
the effects of iron on osteoclastogenesis
and OCL activity (Figure 1), additional
studies will be needed to resolve the
overall impact of iron metabolism on
bone.
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Figure 1. Potential Effects of Iron Transferrin on Bone
In this model, iron transferrin induces mitochondrial production of reactive
oxygen species (ROS) in both osteoclast and osteoblast precursors. This
results in activation of CREB, which in turn increases mitochondrial biogenesis
with increased production of ROS, creating a positive feedback loop.
Increased mitochondrial biogenesis then cooperates with signaling pathways
involved in differentiation of osteoblasts and osteoclasts to increase their
formation and activity.406 Cell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc.
